Changes in T-lymphocyte subpopulations in patients with colorectal cancer before and after acupoint catgut embedding acupuncture observation

Caide Yang; Jinlian Bao; Dengke Li

doi:10.1515/biol-2022-1060

Article Open Access

Changes in T-lymphocyte subpopulations in patients with colorectal cancer before and after acupoint catgut embedding acupuncture observation

Caide Yang , Jinlian Bao and Dengke Li

Published/Copyright: May 20, 2025

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information Explore this Subject

From the journal Open Life Sciences Volume 20 Issue 1

Abstract

This study aims to explore changes in peripheral blood T-lymphocyte subsets in colorectal cancer (CRC) patients before and after acupoint catgut embedding (ACE) acupuncture observation. Eighty CRC surgical patients who visited from April 2017 to May 2022 were selected as study samples using the convenience sampling method. Patients were randomly divided into a control group (n = 40, receiving conventional chemotherapy) and an observation group (n = 40, receiving 4 weeks of additional ACE acupuncture). The observation group showed higher rates of complete and partial remission compared to the control, though the difference was not statistically significant (P > 0.05). The observation group experienced less reduction in CD³⁺, CD⁴⁺ T lymphocytes, and natural killer cells during chemotherapy. Compared with the control group, the percentage of CD³⁺ and CD⁴⁺ T cells in the observation group significantly increased after the intervention, while CD⁸⁺ T-cell levels decreased. The CD⁴⁺/CD⁸⁺ ratio was at a higher level, and the discrepancy was statistically obvious (P < 0.05). Acupuncture therapy can maintain the normal distribution of peripheral blood T-lymphocyte subpopulations during chemotherapy in patients with CRC, thus better maintaining the immune status of patients.

Graphical abstract

Keywords: colorectal cancer; acupoint catgut embedding; T lymphocytes; immunoregulation

1 Introduction

Colorectal cancer (CRC) is one of the malignant tumors worldwide, with a high incidence rate and high recurrence rate [1]. CRC patients often experience postoperative recurrence due to residual small tumors and host cell immune dysfunction, which seriously affects their clinical efficacy and quality of life [2]. Postoperative neoadjuvant chemotherapy (PNC) is a commonly used observation method in clinical practice to prevent CRC recurrence, which can reduce patient mortality [3]. Oxaliplatin, fluorouracil, and capecitabine [4] are commonly used drugs for PNC [5]. As an increasingly common observation option for CRC patients, PNC faces challenges such as limited tumor targeting and common side effects such as gastrointestinal reactions and can also cause immune dysfunction in patients [6].

Currently, oxaliplatin is among the most effective chemotherapy drugs used for CRC observation [7]. During the postoperative chemotherapy stage, adjuvant immunotherapy is usually used for immune regulation, such as 5-fluorouracil or low-dose cyclophosphamide, to strengthen the immune function of the body by inhibiting immunosuppressive cells [8]. The anti-tumor immune response depends on the interaction between tumor cells and immune cells [9]. CRC patients can benefit from immunotherapy strategies that stimulate effector T-cell action [10]. Chemotherapy can lead to a decrease in CD⁴⁺ T lymphocytes and a rise in infiltration of CD⁸⁺ T lymphocytes [11]. CD⁸⁺ T lymphocytes have chemotaxis toward CRC [12]. Intraepithelial lymphocytes play a crucial role in maintaining gastrointestinal epithelial cells and are important cells for the defense of intestinal tumors [13]. Therefore, PNC is an important means to prevent postoperative recurrence of CRC, but it is still necessary to adjust immune function during chemotherapy to reduce its observation side effects.

In the past decade, clinical research on acupoint catgut embedding (ACE) has developed rapidly and has gradually formed relatively standardized and unified operating standards [14]. Moreover, ACE can improve the immune activity of respiratory system cells and reduce lung fiber content [15]. Animal experimental results show that acupoint catgut embedding therapy (ACET) can improve various inflammatory factors in the local microenvironment of rats [16] and has been used in the immune regulation process of liver cancer mice [17]. However, the study on the application of CRC patients is limited, and it is widely used in ulcerative colitis with precancerous lesions [18]. Research has found that acupuncture therapy can bi-directional regulate peripheral blood lymphocytes and neutrophils, thereby improving T-lymphocyte subsets (T-lps) and natural killer (NK) cells, thereby promoting the recovery of immune function in patients after CRC surgery [19]. Acupoint catgut embedding acupuncture therapy (ACEAT) is a new observation technique that combines the advantages of ACET and acupuncture therapy [20]. Based on previous research results, it can be concluded that ACE combined with acupuncture observation can regulate the proportion of T-lps, which is of great significance for improving the body’s immunity.

Cytokines are involved in the process of tumour progression, especially in the context of disturbances in the human tumour microenvironment, where a series of changes in cytokines occur [21]. NK cells are highly regarded for their potential therapeutic value in cancer [22]. At the same time, cytokines are essential for the maturation, activation, and survival of NK cells [23]. To further improve the T-lps ratio in postoperative CRC patients, this study aims to conduct ACEAT for 4 weeks and observe the changes in peripheral blood T-lps ratio before and after observation. Based on the current situation that peripheral blood T-lps imbalance can lead to weakened anti-tumor immune response and poor prognosis in CRC, the research group hypothesizes that ACEAT can adjust the immune status of CRC cases. The specific manifestation is to increase the CD³⁺/CD⁴⁺ T lymphocytes, reduce the CD⁸⁺ T, and make the CD⁴⁺/CD⁸⁺ ratio more balanced. This study can provide a new theoretical basis for the utility of ACEAT in tumor immunity.

2 Materials and methods

2.1 General data

The convenience sampling method selected 80 CRC patients who visited from April 2017 to May 2022 as the study samples. The patients were divided into a control group and an observation group using the red and blue ball method, with 40 patients in each group. Inclusive criteria are as follows: (1) patients diagnosed with colorectal adenocarcinoma through postoperative pathology and treated with colorectal tumor resection surgery; (2) without radiotherapy and chemotherapy observation; (3) Karnofsky physical condition score ≥70 points; (4) expected survival time ≥6 months; and (5) sign an informed consent form. Exclusive criteria are as follows: (1) complication with severe heart, lung, liver, kidney, and other important organ diseases; (2) accompanied by severe coagulation dysfunction or autoimmune diseases; (3) concomitant severe mental illness; (4) recently, received acupuncture and moxibustion observation; (5) poor compliance and inability to complete the experiment; and (6) allergies to the drugs required for the experiment. There was P > 0.05 in gender, age, BMI, tumor stage, tumor site, and distribution of main symptoms among patients, indicating a baseline data balance (Table 1).

Table 1

Comparative data of general characteristics among patients

Group (n)	Gender (n)		Age (years, x ¯ ± s)	BMI (kg/m², x ¯ ± s)	Tumor staging (n)		Main symptoms (n)			Tumor site (n)
Group (n)	Male	Female	Age (years, x ¯ ± s)	BMI (kg/m², x ¯ ± s)	IIB	IIIC	Anemia	Diarrhea	Constipation	Colon	Rectum
Control (40)	25	15	56.1 ± 8.4	24.1 ± 2.4	25	15	13	15	12	18	22
Observation (40)	24	16	55.8 ± 7.5	23.1 ± 2.8	27	13	10	18	12	19	21
χ ²/t	0.053		0.126	0.039	0.220		0.664			1.251
P	0.818		0.900	0.969	0.639		0.717			0.263

Informed consent: Informed consent has been obtained from all individuals included in this study.
Ethical approval: The research related to human use has been complied with all the relevant national regulations and, institutional policies and in accordance with the tenets of the Helsinki Declaration, and has been approved by the Medical Ethics Committee of our institution (Donggang Hospital, The First Hospital of Lanzhou University, No. LZ02016DG12).

2.2 Research method

2.2.1 Control group

Routine observation: on the first day of chemotherapy, 130 mg/m² oxaliplatin (produced by Sanofi Syntherabo France) was administered intravenously, with an intravenous infusion time controlled within 2 h. On the 1st to 14th days of chemotherapy, 1,000 mg/m² capecitabine tablets (produced by Shanghai Roche Pharmaceutical Co., Ltd.), bid, were administered orally. Each chemotherapy cycle in this study lasted 21 days. After the end of one cycle, rest for 7 days and start the next chemotherapy cycle. Chemotherapy is given in conjunction with antiemetic, liver protective, anemia correction, and white blood cell elevation observation and provide nutritional support observation if necessary. When the patient experiences serious adverse reactions or disease progression, chemotherapy should be terminated or other drugs replaced for chemotherapy. At the same time, fake acupuncture and moxibustion intervention are carried out, that is, acupuncture was conducted at 0.5–5 cm beside the “Left Outer Mausoleum, Left Sliding Meat Gate, Guanyuan, Qihai, Zhongwan, Xiawan, Right Outer Mausoleum, and Right Sliding Meat Gate” points, or between the two meridians. After inserting the needle will insert but not be used to avoid getting air. The other methods are similar to the observation group.

2.2.2 Observation group

Perform 4-week ACEAT on the basis of the control group. First, select Left Outer Mausoleum, Left Sliding Meat Gate, Guanyuan, Qihai, Zhongwan, Xiawan, Right Outer Mausoleum, and Right Sliding Meat Gate as ACE acupoints. For routine disinfection of the patient’s skin, use sterile scissors to cut the medical catgut into a length of approximately 1 cm for future use. A No. 8 disposable syringe needle serves as the sleeve, with a No. 28 stainless steel needle used as the core. A section of the thread body is placed on the front end of the buried needle using tweezers. Tweezers serve as a pushing tool to push the segment of the sheep intestine into the needle tube sleeve. Use a filiform needle to pierce the acupoint, and after obtaining qi, push the needle core while exiting the needle tube, so that the sheep intestines can be accurately buried in the acupoint. Perform once before chemotherapy for 7–10 days. Then, remove the catgut under sterile operation. Afterwards, acupuncture observation is carried out. The main acupoints are Shenguan, Taichong, Taixi, Yanglingquan, Shangjuxu, Neiguan, Sanyinjiao, and Zusanli. Use 0.30 mm × 40 mm millineedles. Among them, the three acupoints of Zusanli, Taixi, and Shenguan are injected with the twisting and lifting interpolation method, while the other acupoints use the leveling and reducing method. Inject once every 10 min and keep the needle for 20 min. Once a day, take 2 days off per week for a total of 3 weeks, and the total course of ACEAT is 4 weeks.

2.3 Observed indicators

2.3.1 General information

A general data collection table is used to record the patient’s age, gender, lesion location, BMI, tumor stage, and main symptoms. The data information was collected from the patient’s medical records and was extracted and recorded by two researchers. In cases of data inconsistency, a third researcher reviews and corrects the data.

2.3.2 Clinical effect

Evaluate the postoperative tumor reduction effect on patients and evaluate the clinical efficacy of both groups at 4 weeks after surgery. The therapeutic effect is divided into complete remission (CR): the tumor completely disappears and lasts for more than 4 weeks. Partial remission (PR): the maximum diameter of the tumor decreases by more than 30% and lasts for more than 4 weeks. Disease stability (SD): reduce insufficient PR and increase no more than PD. Disease progression (PD): the maxtumor diameter rises by more than 20% or new lesions appear.

2.3.3 T lymphocytes

Sample collection: 2 ml of blood is drawn from the elbow vein on an empty stomach in the morning and EDTA is added as an anticoagulant during the before, during, and after chemotherapy cycles. The two were thoroughly mixed. This study uses a BD FACSCALIBUR flow cytometer equipped with CellQuest software for data analysis. Analysis method: 100 μl of whole blood sample is taken, corresponding monoclonal antibodies (mAbs) are added, and incubated for 15 min. 10% fetal bovine serum is added to the complete culture medium to ensure a final volume of 100 μl. Red blood cell lysis and washing are performed and resuspended in phosphate-buffered saline (PBS) for machine detection. The determination of CD³⁺, CD⁴⁺, and CD⁸⁺ T cells is performed using a combination of mAbs. The determination of NK cells is carried out using a combination of CD3FITC/CD16CD56PE mAbs. 20 μl of two appropriate combinations of mAbs is added to each sample tube and incubated at 4°C for 30 min to allow the mAbs to bind to the corresponding antigens on the cell surface. Cells are washed twice with cold PBS to remove unbound antibodies, and red blood cell lysis is performed to eliminate interference from red blood cells. Cells are fixed with 1% formaldehyde to maintain cell structure and reduce degradation. The loss cell analyzer is applied for analysis, the detector voltage is set according to the same type of control tube, and compensation is adjusted using a single positive tube to reduce spectral overlap or fluorescence leakage. A total of 10,000 gated events are collected. These events are validated as PBMCs based on physical characteristics (FSC and SSC) and CD45 expression (>95% CD⁴⁵⁺ cells), and data analysis is performed using CellQUEST software. Based on the gating strategies of CD45 and SSC/FSC, the T-cell population is determined and further subdivided into CD⁴⁺ and CD⁸⁺ T-cell subsets. NK cells are analyzed based on the expression of CD3 and CD16/CD56. Detection indicators: Detect the percentage of CD³⁺, CD⁴⁺, and CD⁸⁺ T lymphocytes. Quality control: Set the same type of control sample and adjust the four quadrants of the volume scatter plot to ensure accurate clustering. Read the results and record the percentage of T lymphocytes in different subgroups. Calculate the CD⁴⁺/CD⁸⁺ ratio.

2.4 Statistical methods

All data were analyzed using SPSS 22.0. The measurement data were represented by x ¯ ± s, and independent sample t-tests were utilized for comparison between the two groups. Paired t-tests were taken to compare between the two time points. The comparison of counting data adopted a χ ²-test. Draw a bar chart using GraphPad software to display the ratio of T lymphocytes in different subpopulations. All tests were bilateral tests. P < 0.05 means statistically significant differences. Pearson correlation analysis was used to determine the correlation between ACEAT treatment and T-lymphocyte subsets and NK cells.

3 Results

3.1 Clinical efficacy of patients

In Table 2, compared with the control, the observation group had more cases of CR and PR and fewer cases of SD and PD. Although the observation group had better efficacy evaluation indicators than the control group, the differences in CR, PR, SD, and PD between the groups did not reach statistical significance. In Figure 1, the therapeutic effect of patients in the observation group is concentrated on PR, while the control group is more concentrated on SD. The observation group has an obvious improvement.

Table 2

Comparison of clinical efficacy (n [%])

Group (n)	CR	PR	SD	PD
Control (40)	2 (5.0)	15 (37.5)	18 (45.0)	5 (12.5)
Observation(40)	5 (12.5)	20 (50.0)	12 (30.0)	3 (7.5)
Z	−1.871
P	0.061

Figure 1

Comparative results of clinical efficacy. Note: “ns” is P > 0.05.

3.2 Changes in T lymphocytes in patients

Compared with the control, the observation group had a higher percentage of CD³⁺, CD⁸⁺ T lymphocytes, and NK cells on the 7th day of chemotherapy, and a higher percentage of CD⁴⁺ T lymphocytes on the 4th week of chemotherapy, with a statistically obvious difference (P < 0.05). Compared with before and after chemotherapy, the observation group showed a decrease in CD³⁺, CD⁴⁺ T cells and NK cells on the 7th and 4th weeks of chemotherapy compared to before, while CD⁸⁺ T lymphocytes increased on the 7th day of chemotherapy compared to before, with a statistically significant difference (P < 0.05). This proved that in contrast with the control, the observation showed a lighter degree of inhibition of T-lps during chemotherapy (Table 3). In Figure 2, the observation group showed a slow downward trend in CD³⁺ (%), CD⁴⁺ (%), and NK cells (%), with a slower decline compared to the control group and CD⁸⁺ (%) tended to first increasing and then decreasing.

Table 3

Comparison of T-lymphocyte changes [ x ¯ ± s]

Group	Time	CD³⁺ (%)	CD⁴⁺ (%)	CD⁸⁺ (%)	NK cells (%)
Control	Before chemotherapy cycles	67.1 ± 5.5	38.1 ± 2.8	25.5 ± 2.4	18.3 ± 2.3
	During chemotherapy cycles	59.9 ± 5.7	33.5 ± 4.8	24.4 ± 3.3	15.4 ± 2.3
	After chemotherapy cycles	59.8 ± 6.1	30.6 ± 4.2	23.9 ± 2.8	14.3 ± 2.5
Observation	Before chemotherapy cycles	66.4 ± 4.7	37.8 ± 3.0	24.5 ± 2.4	19.0 ± 2.2
	During chemotherapy cycles	63.3 ± 4.9*^#	36.3 ± 4.7*	25.6 ± 3.5*^#	17.6 ± 3.1*^#
	After chemotherapy cycles	62.5 ± 7.0^#	33.8 ± 3.9*^#	24.3 ± 3.4	16.8 ± 2.9*^#

Note: Compared with the control during the same period, *P < 0.05. Compared with before chemotherapy in this group, ^# P < 0.05.

Figure 2

Trend of T-lymphocyte changes in two groups of patients. Note: (a) CD³⁺ (%); (b) CD⁴⁺ (%); (c) CD⁸⁺ (%); and (d) NK cells (%).

3.3 Changes in CD⁴⁺/CD⁸⁺ ratios between two groups

In Figure 3, there was no statistically significant discrepancy in the CD⁴⁺/CD⁸⁺ ratio between the two groups before chemotherapy. On the 7th day of chemotherapy, the CD⁴⁺/CD⁸⁺ ratio in both groups decreased compared to before chemotherapy, but there was P > 0.05 between the groups. In the 4th week of chemotherapy, the CD⁴⁺/CD⁸⁺ ratio in the control group significantly decreased compared to before and on the 7th day of chemotherapy, while there was no statistically significant difference between the observation group and before chemotherapy. The comparison of CD⁴⁺/CD⁸⁺ ratio at week 4 of chemotherapy showed that the observation group greatly outperformed the control. The results indicate that the observation group can inhibit the decrease in the CD⁴⁺/CD⁸⁺ ratio caused by chemotherapy.

Figure 3

Changes in CD⁴⁺/CD⁸⁺ in two groups of patients. Note: (a) is a comparison bar chart between CD⁴⁺/CD⁸⁺ groups and (b) line chart comparing CD⁴⁺/CD⁸⁺ groups.

3.4 The correlation between ACEAT, T lymphocytes, and NK cells

Before chemotherapy cycles, there was no significant correlation between T-lymphocyte subsets, NK cells, and ACEAT; during chemotherapy cycles and after chemotherapy cycles, there was a positive correlation (P < 0.01) between CD³⁺ (%), CD⁴⁺ (%), NK cells (%), and ACEAT. The detailed information is shown in Table 4.

Table 4

Correlation between ACEAT and T-lymphocyte subsets and NK cells at different time points

Time	CD³⁺ (%)	CD⁴⁺ (%)	CD⁸⁺ (%)	NK cells (%)	CD⁴⁺/CD⁸⁺
Before chemotherapy cycles	−0.066	−0.056	−0.191	0.163	0.121
During chemotherapy cycles	0.307**	0.291**	0.172	0.367**	0.109
After chemotherapy cycles	0.206	0.372**	0.055	0.424**	0.243

Note: **P < 0.01.

3.5 The immune regulatory pathway of ACEAT on T lymphocytes and NK cells

Combined with the acupuncture and moxibustion system immune regulation mechanism diagram drawn by Wang et al. [24] and the research results in this article, the action path of ACEAT on T lymphocytes and NK cells is sorted out, as shown in Figure 4.

Figure 4

Immune regulatory pathways of ACEAT on T lymphocytes and NK cells.

4 Discussion

This study observed the changes in peripheral blood T-lps in CRC patients undergoing routine chemotherapy combined with ACEAT. The results showed that patients who received additional ACEAT had less inhibition of CD³⁺, CD⁴⁺ T and NK cells during chemotherapy compared to the control group who only received conventional chemotherapy. This may be related to the immune regulatory effects of ACE and acupuncture observation. Research has shown that acupoint acupuncture stimulation can improve the Th1 cells, reduce the Th2 cells, and promote cellular immune balance in patients with advanced non-small-cell lung cancer (NSCLC) [25]. Therefore, ACET can alleviate the immuno-suppressive effect caused by chemotherapy. In addition, this study found that ACEAT can increase the ratio of CD³⁺ and CD⁴⁺ T cells after chemotherapy, reduce the CD⁸⁺ T cells, and maintain the CD⁴⁺/CD⁸⁺ ratio at a higher level. This indicates that ACE can regulate the normal distribution of T-lps. The reason for this is that a significant decrease in CD⁴⁺ T cells after chemotherapy is a manifestation of impaired immune function [26]. ACEAT can promote a balanced ratio of CD⁴⁺ and CD⁸⁺ cells, helping to maintain normal cellular immune function.

This study also found that receiving ACE observation during chemotherapy can alleviate the immune function decline caused by chemotherapy in CRC patients. Sun et al. [27] and Sui et al. [28] suggested that acupoint therapy can exert anti-tumor effects by regulating the intestinal microbiota, while this study only observed from an immunological perspective. In the future, a more comprehensive evaluation can be conducted by combining the detection of changes in gut microbiota. For example, Inprasit et al. [29] found through mouse model research that ACEAT can increase weight control. Wu et al. [30] found through meta-analysis that ACEAT can reduce abdominal obesity. Moreover, obesity is closely related to intestinal microbiota imbalance. Zhong et al. [31] and Zhang et al. [32] found through meta-analysis that ACE can effectively treat allergic rhinitis and insomnia, and can improve the immune function of insomnia patients. Both of these are immune-related diseases, supporting the immune regulatory effect of ACE, which is consistent with the conclusions of this study. In addition, Li et al. [33] and Gao et al. [34] used percutaneous electrical stimulation of acupoints such as Changshu and Zusanli in tumor patients to observe postoperative functional recovery-related indicators and also achieved positive results. This study adds ACE observation on the basis of acupuncture observation, with different intervention methods. Moreover, this study only focuses on changes in T lymphocytes, but the above literature suggests that more focus should be paid to the recovery of symptoms in the body. Overall, existing studies have shown that ACEAT can potentially enhance the immune status of tumor patients by regulating T lymphocytes, optimizing their sub-population distribution and function. However, further research is needed to confirm the specific mechanism.

Acupuncture and moxibustion may regulate the number of T-cell subsets and NK cells in the peripheral blood by activating the autonomic nervous system and regulating the immune system. Specifically, acupuncture and moxibustion stimulation of acupoints can act on the activities of the dorsal root ganglion under the skin, thus promoting the generation and activation of immune cells. In addition, acupuncture and moxibustion can regulate the expression of cytokines, such as increasing the levels of interleukin-4 and interferon-γ, which play an important role in the proliferation and functional regulation of immune cells. Through these mechanisms, acupuncture and moxibustion can promote the increase of the number of leukocyte subsets in the peripheral blood, including T cells, B cells, and NK cells.

T lymphocytes are essential in anti-tumor immune response. This study preliminarily confirms that ACEAT can alleviate the damage of chemotherapy to the immune function of CRC patients and help maintain the immune status of T lymphocytes. CD⁴⁺ T lymphocytes can differentiate into subgroups such as Th17 and Treg, participating in the immune response regulation of tumor microenvironment [35]. During the progression of the tumor or chemotherapy is a decrease in the percentage of cells [36]. This study observed an increase in the proportion of CD⁴⁺ T lymphocytes, suggesting that ACE may inhibit tumor growth by promoting Th17 differentiation. Inhibiting CD⁴⁺ T-lymphocyte activation and proliferation can further inhibit anti-tumor immune response [37]. P53 can negatively regulate Sirt1 and promote tumor cell apoptosis, while Sirt1 can in turn reduce p53 activity through deacetylation [38]. This is because ACEAT may inhibit tumor growth by down-regulating the p53 pathway. The proportion of CD³⁺ and CD⁸⁺ T lymphocytes is related to tumor prognosis and immunotherapy responsiveness [39], and maintaining their normal distribution is beneficial for improving clinical efficacy. Previous studies have shown that acupuncture therapy can regulate the immune function of the body. For example, research has found that acupuncture combined with moxibustion can regulate the humoral and cellular immunity of patients with thoracic butterfly type high safety arteritis [40]. Other studies show that acupuncture and moxibustion can alleviate allergic airway inflammation by regulating the balance of CD⁴⁺ T-lymphocyte subtypes in experimental asthma mice [41]. At the same time, it was found that early application of fire needles combined with cupping therapy can treat acute herpes zoster by reducing Th17/Treg levels [42]. Acupuncture and moxibustion can improve the cognitive dysfunction of VA rats and regulate their peripheral immune function and inflammation [43]. It has been found that moxibustion can control asthma symptoms by regulating the imbalance of Th17/Treg cells in asthma patients [44]. Moxibustion can increase the amount of T-lps in peripheral blood [45]. Therefore, ACE, as an acupuncture therapy, its mechanism of regulating immune balance and improving T-lymphocyte population is similar to other acupuncture and moxibustion therapies. The results further confirm that ACE can increase the proportion of T-lps in the peripheral blood of colon cancer patients, especially CD³⁺ and CD⁴⁺ T cells, regulate the balance of Th1/Th2 cells, and thus exert anti-tumor effects. There is a positive correlation (P < 0.01) between CD³⁺ (%), CD⁴⁺ (%), NK cells (%) and ACEAT during and after chemotherapy cycles. This further confirms the positive regulatory effect of ACEAT on CD³⁺ (%), CD⁴⁺ (%), and NK cells (%) in this study. This article provides new ideas for the comprehensive observation of CRC and supports the application prospects of chemotherapy combined with ACE observation. In addition, this study revealed some mechanisms by which ACE regulates the immune function of tumor patients, laying the foundation for subsequent research.

4.1 Limitations of the study

However, the study’s sample size is small, and the statistical validity is limited. The conclusion still needs to be verified by expanding the sample size. The observation indicators are relatively single, only focusing on changes in T lymphocytes and not involving comprehensive immunological indicators. The mechanism research is lacking, and the specific molecular mechanism of ACE regulating immunity needs to be further explored.

5 Conclusion

ACE acupuncture, a traditional Chinese medicine regimen, can protect T lymphocytes, inhibit the degree of damage caused by chemotherapy, and maintain the normal distribution of various subgroups of cells. Therefore, it can potentially improve the immune status and anti-tumor ability of CRC patients, but its specific immune regulatory mechanism still needs further research. In the future, the sample size will be further expanded, and large sample randomized controlled studies will be conducted using a multicenter design to improve the statistical strength and scientific evidence level of the results. Adding more systematic observation indicators, not only focusing on T-lymphocyte changes but also detecting more comprehensive immune function-related indicators, such as immunoglobulins, complement, and inflammatory cytokines, to further comprehensively evaluate the immune regulatory effect. Overall, this study has certain clinical significance in exploring the immune regulatory effects of ACE, but there are still issues such as small sample size, single indicators, and unclear mechanisms that need further optimization to improve the persuasiveness and scientific value of the study.

Funding information: The research is supported by Scientific Research Projects of China Association for the Promotion of Traditional Chinese Medicine in 2019 (No. 2019-11); Scientific Research Projects of China Association for the Promotion of Traditional Chinese Medicine in 2019 (No. 2019-12); Scientific Research Projects of China Association for the Promotion of Traditional Chinese Medicine in 2021 (No. 2021-09); and Scientific Research Projects of China Association for the Promotion of Traditional Chinese Medicine in 2021 (No. 2021-10).
Author contributions: Caide Yang: study design, manuscript preparation, and data collection. Jinlian Bao: statistical analysis and funds collection. Dengke Li: literature search and data interpretation. All authors have participated sufficiently in the work and agreed to be accountable for all aspects of the work.
Conflict of interest: Authors state no conflict of interest.
Data availability statement: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

[1] Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145–64.10.3322/caac.21601Search in Google Scholar PubMed

[2] Liang Q, Chen J, Hou S, Li D, Zhu Y, Li R, et al. Activatable Mn(2+)-Armed nanoagonist augments antitumor immunity in colorectal cancer: A NIR-II Photonic neoadjuvant paradigm. Biomaterials. 2023;300:122206.10.1016/j.biomaterials.2023.122206Search in Google Scholar PubMed

[3] Wong P, Victorino GP, Miraflor E, Alseidi A, Maker AV, Thornblade LW. Impact of safety-net hospital burden on achievement of textbook oncologic outcomes following resection in for stage I-IV colorectal cancer. J Surg Oncol. 2024;129(2):284–96.10.1002/jso.27474Search in Google Scholar PubMed

[4] Ling J, Lin Z, Shi L, Lin Y, Liu X, Lin J, et al. Capecitabine maintenance therapy in metastatic colorectal cancer patients with no evidence of disease: CAMCO trial. Future Oncol. 2023;19(30):2045–54.10.2217/fon-2023-0149Search in Google Scholar PubMed

[5] Ou FS, Walden DJ, Larson JJ, Kang S, Griswold CR, Ueberroth BE, et al. Changes in prescribing patterns in stage III colon cancer. J Natl Compr Canc Netw. 2023;21(8):841–50.e4.10.6004/jnccn.2023.7028Search in Google Scholar PubMed

[6] Huang N, Lu Y, Wang R, Gao P, Liu G. Clinical benefits of FOLFOXIRI combined with bevacizumab for advanced-stage primary signet ring cell carcinoma of the appendix: A case report. Medicine (Baltimore). 2023;102(31):e34412.10.1097/MD.0000000000034412Search in Google Scholar PubMed PubMed Central

[7] Liu Z, Fan L, Niu D, Chen M, Zhang W, Liu Y, et al. Copper(II) complex of salicylate phenanthroline induces the apoptosis of colorectal cancer cells, including oxaliplatin‑resistant cells. Oncol Rep. 2023;50(3):170.10.3892/or.2023.8607Search in Google Scholar PubMed PubMed Central

[8] Peña M, Mesas C, Perazzoli G, Martínez R, Porres JM, Doello K, et al. Antiproliferative, antioxidant, chemopreventive and antiangiogenic potential of chromatographic fractions from anemonia sulcata with and without its symbiont symbiodinium in colorectal cancer therapy. Int J Mol Sci. 2023;24(14):11249.10.3390/ijms241411249Search in Google Scholar PubMed PubMed Central

[9] Ma H, Fang W, Li Q, Wang Y, Hou S. Arf1 ablation in colorectal cancer cells activates a super signal complex in DC to enhance anti-tumor immunity. Adv Sci (Weinh). 2023;10:e2305089.10.1002/advs.202305089Search in Google Scholar PubMed PubMed Central

[10] Anderson TS, McCormick AL, Daugherity EA, Oladejo M, Okpalanwaka IF, Smith SL, et al. Listeria-based vaccination against the pericyte antigen RGS5 elicits anti-vascular effects and colon cancer protection. Oncoimmunology. 2023;12(1):2260620.10.1080/2162402X.2023.2260620Search in Google Scholar PubMed PubMed Central

[11] Wang Y, Gui M, Qu L, Zou M, Gao F. Astragalus polysaccharide inhibits IDO1 expression in colon tumor microenvironment to increase intratumoral CD8∼+ T cell infiltration. Zhongguo Zhong Yao Za Zhi. 2023;48(17):4722–30.Search in Google Scholar

[12] Kong J, Xu S, Zhang P, Zhao Y. CXCL1 promotes immune escape in colorectal cancer by autophagy-mediated MHC-I degradation. Hum Immunol. 2023;84(12):110716.10.1016/j.humimm.2023.09.002Search in Google Scholar PubMed

[13] Yakou M, Ghilas S, Tran K, Liao Y, Afshar-Sterle S, Kumari A, et al. TCF-1 limits intraepithelial lymphocyte antitumor immunity in colorectal carcinoma. Sci Immunol. 2023;8(88):eadf2163.10.1126/sciimmunol.adf2163Search in Google Scholar PubMed

[14] Cheng L, Liang X, Hou X, Nie H, Li L, Lu Y, et al. Bibliometric analysis on key elements of clinical application of acupoint catgut embedding therapy in recent ten years. Zhen Ci Yan Jiu. 2022;47(9):830–6.Search in Google Scholar

[15] Liu J, Gu J, Hu Q, Yue G, Liu L, Tu X, et al. Effect of catgut implantation at “Yingxiang”(LI20) on lower airway remodeling in allergic rhinitis rats. Zhen Ci Yan Jiu. 2020;45(6):461–7.Search in Google Scholar

[16] Zhang Q, Li L, Hou X, Liang X, Lu Y, Nie H, et al. Effect of catgut implantation on macrophage CD68, tumor necrosis factor-α and interleukin-1β in “Zusanli” (ST 36) region of rats. Zhen Ci Yan Jiu. 2023;48(7):681–5.Search in Google Scholar

[17] Xu S, Luo H, Huang B, Yu L, Luo S, Hu H, et al. Therapeutic effect of catgut implantation at acupoint in a mouse model of hepatocellular carcinoma by suppressing immune escape. Evid Based Complement Altern Med. 2022;2022:5572869.10.1155/2022/5572869Search in Google Scholar PubMed PubMed Central

[18] Lu J, Zhou J, Wang L, Zhong C, Chen X, Jia B. Efficacy and safety evaluation of acupoint embedding for patients with ulcerative colitis: A protocol of systematic review and meta-analysis. Medicine (Baltimore). 2020;99(34):e21812.10.1097/MD.0000000000021812Search in Google Scholar PubMed PubMed Central

[19] Zhang S, Du Y. Effects of warming needle moxibustion on improvement of gastrointestinal and immune function in patients with postoperation of colorectal cancer. Zhongguo Zhen Jiu. 2011;31(6):513–7.Search in Google Scholar

[20] Chen X, Huang W, Wei D, Ding D, Jiao Y, Pan H, et al. Clinical effect of catgut implantation at acupoints for the treatment of simple obesity: A multicentre randomized controlled trial. Medicine (Baltimore). 2020;99(48):e23390.10.1097/MD.0000000000023390Search in Google Scholar PubMed PubMed Central

[21] Jurisic V. Multiomic analysis of cytokines in immuno-oncology. Expert Rev Proteom. 2020;17(9):663–74.10.1080/14789450.2020.1845654Search in Google Scholar PubMed

[22] Zimmer J, Jurišić V. Special issue “new developments in natural killer cells for immunotherapy”. Cells. 2023;12(11):1496.10.3390/cells12111496Search in Google Scholar PubMed PubMed Central

[23] Konjević GM, Vuletić AM, Mirjačić Martinović KM, Larsen AK, Jurišić VB. The role of cytokines in the regulation of NK cells in the tumor environment. Cytokine. 2019;117:30–40.10.1016/j.cyto.2019.02.001Search in Google Scholar PubMed

[24] Wang M, Liu W, Ge J, Liu S. The immunomodulatory mechanisms for acupuncture practice. Front Immunol. 2023;14:1147718.10.3389/fimmu.2023.1147718Search in Google Scholar PubMed PubMed Central

[25] Lin G, Lin L, Zhang Y, Pei W, Zeng J, Zhao W. Influence of fire needle stimulation at Sihua acupoints on performance status and Th1/Th2 balance in the patients with advanced non-small cell lung cancer after chemotherapy. Zhen Ci Yan Jiu. 2019;44(2):136–9.Search in Google Scholar

[26] Redman JM, Tsai YT, Weinberg BA, Donahue RN, Gandhy S, Gatti-Mays ME, et al. A randomized phase II trial of mFOLFOX6+ bevacizumab alone or with AdCEA vaccine+ avelumab immunotherapy for untreated metastatic colorectal cancer. Oncologist. 2022;27(3):198–209.10.1093/oncolo/oyab046Search in Google Scholar PubMed PubMed Central

[27] Sun H, Zhang B, Qian H, Chen Z. Effect of warm-needle moxibustion intervention on immune function and intestinal flora in patients after colorectal cancer radical operation. Zhen Ci Yan Jiu. 2021;46(7):592–7.Search in Google Scholar

[28] Sui H, Zhang L, Gu K, Chai N, Ji Q, Zhou L, et al. YYFZBJS ameliorates colorectal cancer progression in Apc(Min/+) mice by remodeling gut microbiota and inhibiting regulatory T-cell generation. Cell Commun Signal. 2020;18(1):113.10.1186/s12964-020-00596-9Search in Google Scholar PubMed PubMed Central

[29] Inprasit C, Huang Y, Lin Y. Evidence for acupoint catgut embedding treatment and TRPV1 gene deletion increasing weight control in murine model. Int J Mol Med. 2020;45(3):779–92.10.3892/ijmm.2020.4462Search in Google Scholar PubMed PubMed Central

[30] Wu X, Chen G, Li Y, Xu Y. The key issues and corresponding strategy of acupoint medicated catgut embedding therapy. Zhongguo Zhen Jiu. 2019;39(1):81–5.Search in Google Scholar

[31] Zhong J, Shen Y, Liu S, Dai M, Yang Y, Zhang D, et al. The effectiveness of catgut implantation at acupoints for allergic rhinitis: A protocol for a systematic review and meta-analysis. Medicine (Baltimore). 2019;98(52):e18554.10.1097/MD.0000000000018554Search in Google Scholar PubMed PubMed Central

[32] Zhang X, Tang C, Luo X, Deng B. A meta-analysis of effectiveness of acupoint catgut embedding therapy for Insomnia. Zhen Ci Yan Jiu. 2018;43(9):591–6.Search in Google Scholar

[33] Li H, Huang W, Du K, Liu W, Wu Z, Xu B, et al. Governor vessel moxibustion for cancer-related fatigue in colorectal patients: a randomized trial. Front Oncol. 2023;13:1199200.10.3389/fonc.2023.1199200Search in Google Scholar PubMed PubMed Central

[34] Gao W, Li W, Yan Y, Yang R, Zhang Y, Jin M, et al. Transcutaneous electrical acupoint stimulation applied in lower limbs decreases the incidence of paralytic ileus after colorectal surgery: A multicenter randomized controlled trial. Surgery. 2021;170(6):1618–26.10.1016/j.surg.2021.08.007Search in Google Scholar PubMed

[35] Kubick N, Paszkiewicz J, Bieńkowska I, Ławiński M, Horbańczuk JO, Sacharczuk M, et al. Investigation of mutated in colorectal cancer (MCC) gene family evolution history indicates a putative role in Th17/treg differentiation. Int J Mol Sci. 2023;24(15):11940.10.3390/ijms241511940Search in Google Scholar PubMed PubMed Central

[36] Colović N, Jurišić V, Terzić T, Jevtovic D, Colović M. Alveolar granulocytic sarcoma of the mandible in a patient with HIV. Onkologie. 2011;34(1–2):55–8.10.1159/000317351Search in Google Scholar PubMed

[37] Francica BJ, Holtz A, Lopez J, Freund D, Chen A, Wang D, et al. Dual blockade of EP2 and EP4 signaling is required for optimal immune activation and antitumor activity against prostaglandin-expressing tumors. Cancer Res Commun. 2023;3(8):1486–500.10.1158/2767-9764.CRC-23-0249Search in Google Scholar PubMed PubMed Central

[38] Brockmueller A, Buhrmann C, Shayan P, Shakibaei M. Resveratrol induces apoptosis by modulating the reciprocal crosstalk between p53 and Sirt-1 in the CRC tumor microenvironment. Front Immunol. 2023;14:1225530.10.3389/fimmu.2023.1225530Search in Google Scholar PubMed PubMed Central

[39] Hijazi A, Antoniotti C, Cremolini C, Galon J. Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response. Oncoimmunology. 2023;12(1):2243169.10.1080/2162402X.2023.2243169Search in Google Scholar PubMed PubMed Central

[40] Ni G, Shi X, Han J, Gao Q, Yan L, Cai G, et al. Effect of acupuncture plus moxibustion on immune function in patients with bra-chiocephalic Takayasu Arteritis. Zhen Ci Yan Jiu. 2018;43(12):777–80.Search in Google Scholar

[41] Dong M, Wang W, Chen J, Li M, Xu F, Cui J, et al. Acupuncture regulates the balance of CD4(+) T cell subtypes in experimental asthma mice. Chin J Integr Med. 2019;25(8):617–24.10.1007/s11655-018-3055-6Search in Google Scholar PubMed

[42] Zeng JC, Liao YZ, Li JJ, Lu LH, Li HZ, Lu LM, et al. Clinical efficacy of fire needling combined with cupping therapy on herpes zoster of acute stage and the effect on Th17/Treg cellular immune balance. Zhongguo Zhen Jiu. 2023;43(10):1128–33.Search in Google Scholar

[43] Pan P, Ma Z, Zhang Z, Ling Z, Wang Y, Liu Q, et al. Acupuncture can regulate the peripheral immune cell spectrum and inflammatory environment of the vascular dementia rat, and improve the cognitive dysfunction of the rats. Front Aging Neurosci. 2021;13:706834.10.3389/fnagi.2021.706834Search in Google Scholar PubMed PubMed Central

[44] Qiao Y, Lei HT, Yi W, Zhao CJ, Xia X, Zhou B, et al. Effect of moxa-cone moxibustion at lung’s back-shu points and front-mu points on Th17/Treg balance in mice with asthma. Zhongguo Zhen Jiu. 2020;40(11):1217–22.Search in Google Scholar

[45] Liu L, Xing X, He D, Yang W, Zhang M, Wu W, et al. Effect of moxibustion on clinical symptoms, peripheral inflammatory indexes and T lymphocyte subsets in COVID-19 patients. Zhongguo Zhen Jiu. 2020;40(12):1271–5.Search in Google Scholar

Received: 2024-07-30

Revised: 2025-01-13

Accepted: 2025-01-14

Published Online: 2025-05-20

This work is licensed under the Creative Commons Attribution 4.0 International License.

Articles in the same Issue

https://doi.org/10.1515/biol-2022-1060

Keywords for this article

colorectal cancer; acupoint catgut embedding; T lymphocytes; immunoregulation

Creative Commons

BY 4.0

Changes in T-lymphocyte subpopulations in patients with colorectal cancer before and after acupoint catgut embedding acupuncture observation

Article

Abstract

Graphical abstract

1 Introduction

2 Materials and methods

2.1 General data

2.2 Research method

2.2.1 Control group

2.2.2 Observation group

2.3 Observed indicators

2.3.1 General information

2.3.2 Clinical effect

2.3.3 T lymphocytes

2.4 Statistical methods

3 Results

3.1 Clinical efficacy of patients

3.2 Changes in T lymphocytes in patients

3.3 Changes in CD4+/CD8+ ratios between two groups

3.4 The correlation between ACEAT, T lymphocytes, and NK cells

3.5 The immune regulatory pathway of ACEAT on T lymphocytes and NK cells

4 Discussion

4.1 Limitations of the study

5 Conclusion

References

Articles in the same Issue

Articles in the same Issue

Articles in the same Issue

3.3 Changes in CD⁴⁺/CD⁸⁺ ratios between two groups